What are the best management options for a patient experiencing extreme fatigue while taking Lacosamide (Vimpat) 100mg twice a day and Briviact (Brivaracetam)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a patient experiencing extreme fatigue while taking Lacosamide (Vimpat) 100mg twice daily and Brivaracetam (Briviact), the most effective management strategy is to prioritize non-pharmacological interventions, focusing on lifestyle modifications and behavioral changes, as there is limited evidence supporting the efficacy of pharmacological treatments for fatigue in this context. The patient should be advised to engage in moderate-intensity physical activity, such as walking, cycling, or swimming, for at least 30 minutes, five or more days a week, as this has been shown to reduce fatigue in various patient populations 1. Additionally, promoting access to multi-component, group psycho-education programs targeted at self-management of fatigue, including components such as coping with emotions, understanding of fatigue, healthy sleep, positive peer reinforcement, overcoming barriers, and opportunity to share experiences, can be beneficial 1. It is also crucial to ensure adequate sleep hygiene, encourage regular meals, and proper hydration, as these factors can significantly impact fatigue levels. Blood tests should be performed to rule out other causes of fatigue, such as anemia, thyroid dysfunction, or vitamin deficiencies. Consultation with a neurologist about potentially adjusting the timing or dose of Lacosamide and Brivaracetam may also be necessary to minimize their contribution to fatigue, although this should be done under medical supervision to avoid precipitating seizures. Recent guidelines suggest that health professionals should incorporate regular assessment of fatigue severity, impact, and coping strategies into clinical consultations, and that addressing fatigue should be part of usual clinical care 1. However, the use of psychostimulants, such as modafinil, is not universally recommended due to mixed evidence regarding their efficacy in treating fatigue in cancer patients and other conditions 1. Therefore, a comprehensive approach that includes lifestyle modifications, behavioral changes, and careful management of underlying medical conditions is likely to yield the best outcomes in terms of reducing fatigue and improving quality of life.

From the Research

Management Options for Extreme Fatigue

The patient is experiencing extreme fatigue while taking Lacosamide (Vimpat) 100mg twice a day and Briviact (Brivaracetam). To manage this condition, consider the following options:

  • Review the patient's medication regimen to identify potential interactions or side effects that may be contributing to the fatigue 2, 3.
  • Assess the patient's overall health and medical history to determine if there are any underlying conditions that may be causing the fatigue.
  • Consider adjusting the dosage of Lacosamide, as the current dose may be too low to achieve optimal efficacy, or too high, leading to increased side effects such as fatigue 4, 5.
  • Monitor the patient's plasma Lacosamide concentrations to ensure they are within the therapeutic range, as subtherapeutic levels may lead to reduced efficacy, while supratherapeutic levels may increase the risk of side effects 6.

Potential Side Effects of Lacosamide

Lacosamide has been associated with several side effects, including:

  • Dizziness 4, 2, 3
  • Nausea 4, 2, 3
  • Headache 2, 3
  • Fatigue, although this is not a commonly reported side effect in clinical trials 2, 3

Pharmacokinetics and Drug Interactions

Lacosamide has a relatively low potential for drug interactions, as it does not induce or inhibit enzymes of the cytochrome P450 system 2, 3. However, it is still important to review the patient's medication regimen to identify any potential interactions. The elimination half-life of Lacosamide is approximately 13 hours, and it is primarily eliminated through hepatic and renal mechanisms 6, 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Lacosamide.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.